TWO NEW new modified phosphoramidites have been launched to complement Link Technologies’s oligonucleotide synthesis support portfolio.
Triplex, antisense, and gene targeting research may benefit from the company’s new RNA-type phosphoramidites, which it says provide nuclease resistance and stability.
New ethyl phosphoramidites are said to improve oligonucleotide stability and delivery into cells, which is helpful in therapeutic applications.
The modified RNA-type phosphoramidites comprise two new 2’-OMe RNA products, 2’-OMe-I and 2’-OMe-T. These are suitable for triplex, antisense, and gene targeting studies, as they form more stable hybrids with complementary RNA strands compared to equivalent DNA or RNA strands.
When used in gene targeting studies, the addition of 2’-OMe residues into triplex forming oligonucleotides (TFO’s) confers the same nuclease resistance and stability as seen with duplexes, says Link.
Oligonucleotides synthesised from the company’s new ethyl phosphoramidites (available with standard nucleobase protection) have a neutral charge and slightly lipophilic character, improving their delivery into the cell. Oligonucleotides containing these ethyl groups are nuclease resistant and inhibit protein expression and cell growth when taken up by liposomes.